Lipid nanoparticle delivery systems for siRNA-based therapeutics

Drug Delivery and Translational Research

Volumn 4, Issue 1, 2014, Pages 74-83

  Wan, C ^a,c   Allen, T M ^b   Cullis, P R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Life Sciences Centre   (Canada)

Author keywords

Drug delivery systems; Lipid nanoparticles; LNP siRNA systems; Small interfering RNA; Therapeutics

Indexed keywords

KINESIN; KINESIN SPINDLE PROTEIN; LIPID; LIPID NANOPARTICLE; NANOPARTICLE; POLO LIKE KINASE 1; PREALBUMIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

BODY WEIGHT; ENDOMETRIUM CARCINOMA; FAMILIAL AMYLOID POLYNEUROPATHY; GENE SILENCING; HUMAN; HYPERCHOLESTEROLEMIA; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

EID: 84893624537     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-013-0161-z     Document Type: Review

References (112)

1. Fire A et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669): 806-11.
2. Elbashir SM et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836): 494-8.
3. Ashfaq UA et al. siRNAs: potential therapeutic agents against hepatitis C virus. Virol J. 2011;8: 276.
4. Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm Res. 2008;25(1): 72-86.
5. DeVincenzo J et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107(19): 8800-5.
6. Morrissey DV et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23(8): 1002-7.
7. Subramanya S et al. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther. 2010;10(2): 201-13.
8. Devi GR. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 2006;13(9): 819-29.
9. Martinez LA et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A. 2002;99(23): 14849-54.
10. Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci. 2006;97(8): 689-96.
11. DiFiglia M et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007;104(43): 17204-9.
12. Farah MH. RNAi silencing in mouse models of neurodegenerative diseases. Curr Drug Deliv. 2007;4(2): 161-7.
13. Li T, Koshy S, Folkesson HG. RNA interference for CFTR attenuates lung fluid absorption at birth in rats. Respir Res. 2008;9: 55.
14. Courties G et al. RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2009;9(5): 535-8.
15. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides. 2008;18(4): 305-19.
16. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13(6): 541-52.
17. Zimmermann TS et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(7089): 111-4.
18. Kanasty RL et al. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012;20(3): 513-24.
19. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA. 2003;9(9): 1034-48.
20. Snead NM, Rossi JJ. RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics. Nucleic Acid Ther. 2012;22(3): 139-46.
21. Bangham AD. Membrane models with phospholipids. Prog Biophys Mol Biol. 1968;18: 29-95.
22. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1): 238-52.
23. Deamer DW. From "banghasomes" to liposomes: a memoir of Alec Bangham, 1921-2010. FASEB J. 2010;24(5): 1308-10.
24. Gregoriadis G. Drug entrapment in liposomes. FEBS Lett. 1973;36(3): 292-6.
25. Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med. 1976;295(14): 765-70.
26. Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med. 1976;295(13): 704-10.
27. Gregoriadis G, Ryman BE. Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Biochem J. 1971;124(5): 58P.
28. Huang C. Studies on phosphatidylcholine vesicles. Formation and physical characteristics. Biochemistry. 1969;8(1): 344-52.
29. Schullery SE et al. Fusion of dipalmitoylphosphatidylcholine vesicles. Biochemistry. 1980;19(17): 3919-23.
30. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5(1): 25-44.
31. Hope MJ et al. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta. 1985;812(1): 55-65.
32. Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta. 1986;858(1): 161-8.
33. Szoka F et al. Preparation of unilamellar liposomes of intermediate size (0. 1-0. 2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim Biophys Acta. 1980;601(3): 559-71.
34. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta. 1973;298(4): 1015-9.
35. Stroock AD et al. Chaotic mixer for microchannels. Science. 2002;295(5555): 647-51.
36. Belliveau NM et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids. 2012;1: e37.
37. Zhigaltsev IV et al. Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir. 2012;28(7): 3633-40.
38. 31P NMR studies on sonicated and unsonicated phosphatidylcholine liposomes. Biochim Biophys Acta. 1975;406(1): 6-20.
39. De Kruijff B, Cullis PR, Radda GK. Outside-inside distributions and sizes of mixed phosphatidylcholine-cholesterol vesicles. Biochim Biophys Acta. 1976;436(4): 729-40.
40. Cullis PR et al. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta. 1997;1331(2): 187-211.
41. Fenske DB, Cullis PR. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol. 2005;391: 7-40.
42. Madden TD et al. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids. 1990;53(1): 37-46.
43. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta. 1986;857(1): 123-6.
44. Mayer LD et al. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta. 1990;1025(2): 143-51.
45. Mayer LD et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989;49(21): 5922-30.
46. Zhigaltsev IV et al. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release. 2010;144(3): 332-40.
47. Maeda H et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release Off Journal Control Release Soc. 2000;65(1-2): 271-84.
48. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzym Regul. 2001;41: 189-207.
49. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1): 6387-92.
50. Hashizume H et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156(4): 1363-80.
51. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6(4): 559-93.
52. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res. 2010;2: 14.
53. Sarin H et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med. 2009;7: 51.
54. Kimelberg HK et al. The effect of entrapment in liposomes on the in vivo distribution of [3H]methotrexate in a primate. Cancer Res. 1976;36(8): 2949-57.
55. Gregoriadis G, Neerunjun DE. Control of the rate of hepatic uptake and catabolism of liposome-entrapped proteins injected into rats. Possible therapeutic applications. Eur J Biochem. 1974;47(1): 179-85.
56. Juliano RL, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun. 1975;63(3): 651-8.
57. Hoekstra D, Scherphof G. Effect of fetal calf serum and serum protein fractions on the uptake of liposomal phosphatidylcholine by rat hepatocytes in primary monolayer culture. Biochim Biophys Acta. 1979;551(1): 109-21.
58. Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem. 1992;267(26): 18759-65.
59. Moghimi SM, Patel HM. Differential properties of organ-specific serum opsonins for liver and spleen macrophages. Biochim Biophys Acta. 1989;984(3): 379-83.
60. Papahadjopoulos D et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88(24): 11460-4.
61. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991;1068(2): 133-41.
62. Ishida T et al. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release. 2003;88(1): 35-42.
63. Allen TM et al. Stealth liposomes: an improved sustained release system for 1-beta-d-arabinofuranosylcytosine. Cancer Res. 1992;52(9): 2431-9.
64. Mayhew EG et al. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer. 1992;51(2): 302-9.
65. Vaage J et al. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer. 1992;51(6): 942-8.
66. Bakker-Woudenberg IA et al. Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochim Biophys Acta. 1992;1138(4): 318-26.
67. James ND et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin Oncol (R Coll Radiol). 1994;6(5): 294-6.
68. Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs. 1997;54 Suppl 4: 22-9.
69. Blade J et al. Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk. 2011;11(1): 44-9.
70. Boman NL et al. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994;54(11): 2830-3.
71. Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta. 1993;1152(2): 253-8.
72. Mayer LD et al. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol. 1993;33(1): 17-24.
73. Webb MS et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol. 1998;42(6): 461-70.
74. Webb MS et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72(4): 896-904.
75. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1): 36-48.
76. Felgner PL et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A. 1987;84(21): 7413-7.
77. Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature. 1989;337(6205): 387-8.
78. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001;8(15): 1188-96.
79. Hirko A, Tang F, Hughes JA. Cationic lipid vectors for plasmid DNA delivery. Curr Med Chem. 2003;10(14): 1185-93.
80. Martin B et al. The design of cationic lipids for gene delivery. Curr Pharm Des. 2005;11(3): 375-94.
81. Lappalainen K et al. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res. 1994;11(8): 1127-31.
82. Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta. 1997;1329(2): 345-56.
83. Maurer N et al. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J. 2001;80(5): 2310-26.
84. Semple SC et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta. 2001;1510(1-2): 152-66.
85. Hafez IM, Cullis PR. Roles of lipid polymorphism in intracellular delivery. Adv Drug Deliv Rev. 2001;47(2-3): 139-48.
86. Koltover I et al. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science. 1998;281(5373): 78-81.
87. Heyes J et al. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release. 2005;107(2): 276-87.
88. Jayaraman M et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51(34): 8529-33.
89. Semple SC et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2): 172-6.
90. Ambegia E et al. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta. 2005;1669(2): 155-63.
91. Fenske DB, MacLachlan I, Cullis PR. Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol. 2002;346: 36-71.
92. Wheeler JJ et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 1999;6(2): 271-81.
93. Akinc A et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7): 1357-64.
94. Leung AK et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. J Phys Chem C Nanomater Interfaces. 2012;116(34): 18440-50.
95. Basha G et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther. 2011;19(12): 2186-200.
96. Lee JB et al. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer. 2012;131(5): E781-90.
97. Di Paolo D et al. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther. 2011;19(12): 2201-12.
98. World Gastroenterology Organisation global guideline. Hepatocellular carcinoma (HCC): a global perspective. http://www. worldgastroenterology. org/assets/downloads/en/pdf/guidelines/24_hepatocellular_carcinoma_en. pdf (2009).
99. Mayer TU et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999;286(5441): 971-4.
100. Kapitein LC et al. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature. 2005;435(7038): 114-8.
101. Weil D et al. Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques. 2002;33(6): 1244-8.
102. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2): 114-27.
103. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706): 58-62.
104. Landesman Y et al. In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). Silence. 2010;1(1): 16.
105. Zeldenrust SR, Benson MD. Familial and senile amyloidosis caused by transthyretin. In: Ramirez-Alvarado M, Kelly JW, Dobson C, editors. Protein misfolding diseases: current and emerging principles and therapies. New York: Wiley; 2010.
106. Nagasaka T. Familial amyloidotic polyneuropathy and transthyretin. Subcell Biochem. 2012;65: 565-607.
107. Jacobson DR et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans. N Engl J Med. 1997;336(7): 466-73.
108. Abifadel M et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat. 2010;20(11): 1547-71.
109. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011;216(2): 258-65.
110. Farnier M. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Am J Cardiovasc Drugs. 2011;11(3): 145-52.
111. Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J. 2005;19(6): 611-3.
112. Ramanathan RK, et al., A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, Abstract number LB-289, 6-10 April, Washington, DC; 2013.